Featured Research

from universities, journals, and other organizations

Aggressive blood cancers: Is Pralatrexate effective in patients with T-cell lymphoma who fail ICE-based regimens?

Date:
December 7, 2010
Source:
John Theurer Cancer Center
Summary:
Researchers analyzed data from the phase II pivotal trial of pralatrexate (known as the PROPEL study) -- which led to the FDA approval of pralatrexate in September 2009. Forty percent of study patients treated with pralatrexate showed a partial or complete response. The authors concluded that the efficacy of this medication as a standalone treatment compared favorably to ICE-based regimens.

Andre Goy, M.D., M.S., Deputy Director and Chief, Lymphoma and Director, Clinical and Translational Cancer Research, John Theurer Cancer Center, and colleagues analyzed data from the phase II pivotal trial of pralatrexate (known as the PROPEL study) -- which led to the FDA approval of pralatrexate in September 2009.

The goal of the study was to determine the outcome of the subset of patients with Peripheral T-Cell Lymphoma (PTCL) who had previously received and failed or relapsed after ICE chemotherapy. ICE is a combination of ifosfamide, carboplatin and etoposide, currently used as standard salvage therapy in patients with PTCL in preparation of high dose therapy followed by autologous stem cell transplantation.

PTCL is an especially aggressive cancer that attacks immune cells that protect the body from viruses. It is typically resistant to second-line treatments, such as ICE regimens.

Forty percent of study patients treated with pralatrexate showed a partial or complete response. The authors concluded that the efficacy of this medication as a standalone treatment compared favorably to ICE-based regimens.

"Given the results, we will continue to explore the role of pralatrexate in combination with other agents to build upon its single agent activity. Our investigation will include PTCL patients in relapse and in the frontline setting in an effort to improve outcomes," said Dr. Goy.

This research was presented at the annual meeting of the American Society of Hematology (ASH) taking place December 4-7, 2010 in Orlando, Florida.


Story Source:

The above story is based on materials provided by John Theurer Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

John Theurer Cancer Center. "Aggressive blood cancers: Is Pralatrexate effective in patients with T-cell lymphoma who fail ICE-based regimens?." ScienceDaily. ScienceDaily, 7 December 2010. <www.sciencedaily.com/releases/2010/12/101207125928.htm>.
John Theurer Cancer Center. (2010, December 7). Aggressive blood cancers: Is Pralatrexate effective in patients with T-cell lymphoma who fail ICE-based regimens?. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2010/12/101207125928.htm
John Theurer Cancer Center. "Aggressive blood cancers: Is Pralatrexate effective in patients with T-cell lymphoma who fail ICE-based regimens?." ScienceDaily. www.sciencedaily.com/releases/2010/12/101207125928.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins